Johnson & Johnson's TREMFYA Reduces MRI-Assessed Inflammation In Axial Psoriatic Arthritis
Johnson & Johnson reported that TREMFYA (guselkumab) significantly improved axial symptoms and MRI-assessed inflammation in adults with active psoriatic arthritis (PsA) in a Phase 4 study. At Week 24, TREMFYA showed greater improvements in BASDAI scores and sacroiliac joint inflammation reduction compared to placebo. The stock closed down 2.04% at $267.14 on Thursday, and is up 0.74% in pre-market trading.
How this was made

The 30-second read
Why it matters
Positive efficacy and safety signals could expand the drug's label and revenue outlook, influencing JNJ's valuation.
Market read
New trial data provides fresh catalyst for JNJ stock, potentially prompting short‑term buying interest.
What to watch
Long‑term commercial uptake depends on reimbursement and competition from other IL‑23 inhibitors.
Background
Johnson & Johnson's TREMFYA (guselkumab) is an IL‑23 inhibitor approved for plaque psoriasis; this is the first Phase 4 data in axial psoriatic arthritis.
Ticker impact
Johnson & Johnson reported positive Phase 4 STAR trial results for TREMFYA in axial psoriatic arthritis, showing significant MRI inflammation reduction.
potential modest upside as investors price in the efficacy data
Phase 4 results are new, material clinical information that can shift expectations for future sales and pipeline valuation.
Market effects
May boost confidence in biotech/auto‑immune drug segment and could lift peers with similar pipelines.
U.S. healthcare sector may see slight positive pressure.
Limited to investors tracking J&J and related therapeutic categories.
Counterpoint
If the market has already priced in the trial success, the news could be a short‑term sell‑off on profit taking.
Key entities
- CompanyJohnson & Johnson
U.S. healthcare conglomerate developing TREMFYA.
- DrugTREMFYA (guselkumab)
IL‑23 inhibitor being tested for axial psoriatic arthritis.



